Rigel Pharmaceuticals, Inc. — FY2013 Form 10-K
Business context and reporting period
Clinical-stage drug developer focused on small-molecule treatments for inflammatory and autoimmune diseases and muscle disorders. This annual report covers the fiscal year ended December 31, 2013; selected unaudited quarterly data include Q4 2013 and Q4 2012. Rigel had no commercialized products and relied on collaboration payments and capital markets to fund operations.
Financial performance and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Collaboration revenue | $7.15 million | $2.25 million |
| Research and development expense | $75.33 million | $78.78 million |
| General and administrative expense | $19.61 million | $22.85 million |
| Restructuring charges | $1.68 million | — |
| Operating loss | $89.47 million | $99.38 million |
| Net loss | $89.03 million | $98.84 million |
| Net loss per share, basic and diluted | $1.02 | $1.32 |
| Operating cash flow | $(86.06) million | $(85.19) million |
Q4 2013 revenue was $5.75 million, net loss was $16.86 million and loss per share was $0.19, versus no revenue, a $25.47 million net loss and $0.30 loss per share in Q4 2012. FY2013 revenue comprised a $5.8 million AstraZeneca payment for continued development of R256 and a $1.4 million Daiichi payment related to an oncology IND filing. No royalty revenue was reported.
At year-end, cash, cash equivalents and available-for-sale securities totaled $211.98 million, down $86.27 million from $298.24 million in 2012. Working capital was $209.78 million; total assets were $226.06 million and stockholders’ equity was $208.25 million. The balance sheet reported no debt or capital lease obligations. The company had $62.31 million in future facilities lease payments, including $14.35 million due within one year. Management stated existing capital should fund projected requirements for at least 12 months, but cautioned this depends on assumptions. No off-balance-sheet arrangements creating potential material risks were reported.
Material changes versus the prior comparable period
- Collaboration revenue increased $4.9 million year over year, principally due to the R256 and Daiichi payments; revenue remained small relative to operating costs.
- Operating loss narrowed by $9.91 million. R&D expense fell $3.45 million and G&A fell $3.24 million, primarily reflecting lower stock-based and bonus compensation; increased clinical and preclinical costs partly offset R&D savings.
- Cash and securities declined by approximately $86.3 million. Operating cash use remained high, while 2013 financing proceeds were only $1.05 million, compared with $139.09 million in 2012, which included a public offering.
- AstraZeneca ended its fostamatinib collaboration after Phase 3 rheumatoid arthritis results and returned those rights; Rigel discontinued development for rheumatoid arthritis and lymphoma. The separate AstraZeneca R256 collaboration continued.
- Rigel reduced its workforce by 30 positions (18%) and recorded $1.68 million in restructuring charges.
Outlook, commentary and risks
At the filing date, Rigel planned to conduct the fostamatinib ITP Phase 3 program itself, with two pivotal studies expected to start in 2014 and top-line results anticipated in the second half of 2015. It planned a Phase 2 IgA nephropathy study in summer 2014. R348’s dry-eye Phase 2 results were expected in the second half of 2014, with another Phase 2 study planned for ocular graft-versus-host disease; R118 was expected to enter Phase 1 in the first half of 2014. Management expected R&D expense to increase in 2014 as the ITP program and R348 study advanced. These are forward-looking plans, not guaranteed outcomes.
R343 failed primary and secondary endpoints in an asthma Phase 2 study, and R333 failed its primary endpoint in a DLE Phase 2 study; Rigel discontinued both programs for those indications. The filing identifies substantial risks from clinical failure or delay, regulatory uncertainty, competition, reliance on third-party manufacturers and collaborators, and the need for additional capital. Potential future collaboration milestones exceeding $152.3 million are contingent, uncertain and may never be received. Equity financing could dilute shareholders; management said future funding needs depend on clinical progress and other uncertain factors.
Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. Management and the auditor concluded internal controls were effective as of December 31, 2013. No legal proceedings were reported in the filing.
Important facts for investors to verify
- Whether cash burn and clinical spending preserve the stated minimum 12-month funding runway, especially as Rigel assumes fostamatinib Phase 3 costs.
- Actual initiation, enrollment, safety and efficacy results for the planned fostamatinib ITP and IgA nephropathy studies and R348 trials.
- Progress and timing under the continuing R256/AstraZeneca and other partner agreements; distinguish contingent milestone potential from contracted or received revenue.
- Whether reduced collaboration income, operating losses and the absence of product sales require additional financing, and the resulting dilution or licensing trade-offs.
- Facilities lease commitments, third-party manufacturing availability, and any subsequent changes to pipeline priorities or workforce.